Monitor enrollment progress in the Phase 2 UC trial as a key catalyst; assess whether the Iterative Health partnership meaningfully accelerates timelines. The $3M raise provides limited runway, so future financing needs should be watched.
PALI drugs
PALI drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $1.89entry
- T+1 · 8mo ago +2.12%α +1.64% · $1.93
- T+5 · 7mo ago −3.70%α −7.32% · $1.82
- T+20 · 7mo ago +5.82%α −4.06% · $2.00
- T+60 · 5mo ago +10.58%α −3.58% · $2.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palisade Bio issued 1.54 million shares to an affiliate of Iterative Health for $3.0 million to support a clinical trial partnership for its ulcerative colitis drug PALI-2108. The company also entered into a master services agreement with Iterative Health to accelerate patient enrollment in the upcoming Phase 2 study.
Key Facts
- Palisade Bio issued 1,536,885 shares of common stock to an affiliate of Iterative Health for $3.0 million ($1.952 per share)
- Proceeds support collaboration with Iterative Health to expedite patient enrollment in the Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis
- The share issuance was conducted under a private placement exempt from registration under Section 4(a)(2) of the Securities Act
- The transaction represents approximately 4.9% of Palisade Bio's current market cap of $312M
Financial Impact
$3.0 million in gross proceeds from issuance of 1.54 million shares at $1.952 per share, representing 4.9% dilution based on current market cap
Risk Factors
- Dilution from share issuance may pressure stock price
- Clinical trial delays or poor enrollment despite partnership
- Limited funding size suggests need for additional capital in near term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014822 |
| Document: 0001493152-26-014822-index-headers.html | 0001493152-26-014822 |
| Document: 0001493152-26-014822-index.html | 0001493152-26-014822 |
| Document: 0001493152-26-014822.txt | 0001493152-26-014822 |
Track record
14 reports on PALI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $1.17 Now $1.03 −11.97% settles Dec 10
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
- Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers